Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2008
10/16/2008US20080255076 Steroid-Derived Pharmaceutical Compositions
10/16/2008US20080255075 Treatment or inhibition of a steroid hormone dependent disorder; reducing spermatogenesis or male virility; 17 beta -hydroxysteroid dehydrogenase (17 beta-HSD) inhibitors; compounds such as 3-(benzylamino)-15alpha-(4-morpholin-4-yl-4-oxobutyl)estra-1(10),2,4-trien-17-one
10/16/2008US20080255070 Bisphosphonate Compounds and Methods with Enhanced Potency for Multiple Targets including FPPS, GGPPS, AND DPPS
10/16/2008US20080255066 Two or more antisense oligonucleotides complementary to a thymidylate synthase mRNA; enhanced cancer tissue penetration or neoplastic cellular uptake of antisense agent molecules
10/16/2008US20080255065 In combination with one or more anti-cancer therapeutics inhibits neoplastic cell proliferation; siRNA molecule decreased gemcitabine chemoresistance of pancreatic adenocarcinoma cells in vivo, demonstrating a synergistic effect when administered in combination with gemcitabine
10/16/2008US20080255061 To enhance the sensitivity of drug-resistant tumor cells to chemotherapeutic drugs; treating P-gp or Bcl-2 over-expression, or glyoxylase I over-activity; phthalide derivatives such as dimers and spiro-ring derivatives, obtained as plant extracts from ligusticus wallichii franchet or angelica
10/16/2008US20080255059 Regulators of the hedgehog pathway, compositions and uses related thereto
10/16/2008US20080255056 Salts of isophosphoramide mustard and analogs thereof
10/16/2008US20080255046 Y2 Selective Receptor Agonists for Therapeutic Interventions
10/16/2008US20080255039 Peptide which is part of epitope in human IL-15 responsible for high-affinity binding of IL-15 to IL-15Ralpha chain, characterized in that it has sequence of region of human mature wild-type IL-15 from L44 to L52, or sequence of region of human mature wild-type IL-15 from E64 to I68 or from E64 to L69
10/16/2008US20080255035 Sparc and methods of use thereof
10/16/2008US20080255029 Neuroendocrine Tumor Treatment
10/16/2008US20080255028 Collagen Receptor I-Domain Binding Modulators
10/16/2008US20080255025 Protease inhibition
10/16/2008US20080254506 Claudin polypeptides
10/16/2008US20080254447 Using CpG site methylation of breast cancer tumor antigens as evaluative tools in prognosing/diagnosing cell proliferative disorders
10/16/2008US20080254154 Comprising Cucurbita moschata, Carthamus tinctorius, Plantago asiatica and Lonicera japonica; climacteric disturbance, primary hypogonadism (including ovarian hypofunction and testicular deficiency), Turner's syndrome, Klinefelter's syndrome, gonadotropin-producing tumor, testitis, ovarian amenorrhea
10/16/2008US20080254153 Water Dispersible Composition and Method for Preparing Same
10/16/2008US20080254139 Layer of submucosa, basement membrane, and mucosa; disrupt cells in tumor; apply matrix as liquid or semi-solid, a sheet or a particulate; recruitment of an endogenous stem cell to site; inhibition of abnormally proliferating malignant cells
10/16/2008US20080254138 Layer of submucosa, basement membrane, and mucosa; disrupt cells in tumor; apply matrix as liquid or semi-solid, a sheet or a particulate; recruitment of an endogenous stem cell to site; inhibition of abnormally proliferating malignant cells
10/16/2008US20080254135 Resveratrol-containing compositions for general health and vitality
10/16/2008US20080254127 Inhalation particles incorporating a combination of two or more active ingredients
10/16/2008US20080254116 Delta and Epsilon Crystal Forms of Imatinib Mesylate
10/16/2008US20080254089 Prefilled DAIKYO CZ plastic syringe heat sterilisable; unit dose 2-(imidazol-1yl)-1-hydroxyethane-1 pre-concentrate solution; buffering, isotonising agent; endotoxin, pyrogen-free after autoclaving
10/16/2008US20080254058 Or surface-coupled proteins; a multivalent heterologous protein display vehicle; vaccines for infectious diseases, cancer, allergies, and autoimmune diseases
10/16/2008US20080254040 Antagonists of receptors of enothelial growth factor, platelet-derived growth factor, fibroblast growth factor, epidermal growth factors, HER2, IGF1R, HGFR or c-Kit, which is further an antagonist of a src tyrosine kinase family member, and chemotherapeutic agent; co-treatment with radiation therapy
10/16/2008US20080254032 Colony stimulating bfcator specific monoclonal antibody for use in diagnosis, prevention and treatment of infcetion, cell proliferative, inflammatory, autoimmune, arthritic, skin, respiratory and nervous system disorders
10/16/2008US20080254031 Nucleotide sequences coding tumor antigens for use as diagnostic tool in detection and staging of cell proliferative disorders
10/16/2008US20080254027 Optimized CD5 antibodies and methods of using the same
10/16/2008US20080254021 Tie1-binding ligands
10/16/2008US20080254004 Homogeneous Neural Precursor Cells
10/16/2008US20080253998 Treatment of cancer using tlr3 agonists
10/16/2008US20080253988 Pyrrolo [1,2-D] [1,2-4] Triazine as Inhibitors of C-Jun N Terminal Kinases (Jnk) and P-38 Kinases
10/16/2008US20080253969 Multi-functional polyglutamate drug carriers
10/16/2008US20080253965 Small-Molecule Hsp90 Inhibitors
10/16/2008US20080253963 Tumor markers in ovarian cancer
10/16/2008CA2720982A1 Method of treating brain cancer
10/16/2008CA2684747A1 Salts of isophosphoramide mustard and analogs thereof
10/16/2008CA2683641A1 Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
10/16/2008CA2683434A1 Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry
10/16/2008CA2683431A1 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
10/16/2008CA2683398A1 Fused ring heterocycle kinase modulators
10/16/2008CA2682981A1 Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
10/16/2008CA2682686A1 Methods and systems for treating cell proliferation disorders
10/16/2008CA2682340A1 [2 , 6] naphthyridines useful as protein kinase inhibitors
10/16/2008CA2681560A1 Pteridinone derivatives for use as stearoyl coa desaturase inhibitors
10/16/2008CA2681529A1 2, 6, 9-substituted purine derivatives having anti proliferative properties
10/16/2008CA2681451A1 Anti-tumor activity of temsirolimus in papillary renal cell cancer
10/16/2008CA2680683A1 Wortmannin-rapalog conjugate and uses thereof
10/16/2008CA2678415A1 Wortmannin-rapamycin conjugate and uses thereof
10/15/2008EP1980568A1 Ethinylated hetero dinucleotide phosphate analoga, method for their manufacture and application thereof
10/15/2008EP1980562A1 Taxol derivatives with antitumor activity
10/15/2008EP1980561A1 Substituted 1h-pyrazolo[3,4-b] pyridine derivatives active as kinase inhibitors
10/15/2008EP1980270A2 Agent for photodynamic therapy containing porous silicon and method of quantitative measurement of reactive oxygen species produced therefrom
10/15/2008EP1980265A1 Therapeutic agent
10/15/2008EP1980248A1 Composition for treating cancer cells and synthetic method for the same
10/15/2008EP1980243A1 Liposome preparation
10/15/2008EP1979368A2 Compounds and methods for the treatment of cancer
10/15/2008EP1979357A1 Solid forms of a pyrrolopyrimidine derivative and their use as anti-tumor agents
10/15/2008EP1979353A2 Fused heterobicyclic kinase inhibitors
10/15/2008EP1979342A1 Compounds for the inhibition of integrins and use thereof
10/15/2008EP1979338A1 Cis-4, 5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors
10/15/2008EP1979332A1 Chemical compounds
10/15/2008EP1979328A1 Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
10/15/2008EP1979327A1 Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
10/15/2008EP1979326A1 Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
10/15/2008EP1979314A2 Indole sulfonamide modulators of progesterone receptors
10/15/2008EP1979002A2 Combination of igfr inhibitor and anti-cancer agent
10/15/2008EP1978992A2 Inhibitors of cell migration mediated by h-prune-gsk-3 complex and uses in antitumoral therapy
10/15/2008EP1978991A1 Isolated organ perfusion combination therapy of cancer
10/15/2008EP1978985A2 Anti-hyperproliferative therapies targeting hdgf
10/15/2008EP1978973A2 Methods of using hedgehog kinase antagonists to inhibit hedgehog signaling and to treat hedgehog mediated disorders
10/15/2008EP1978964A2 Jak2 tyrosine kinase inhibition
10/15/2008EP1978958A2 Ret tyrosine kinase inhibition
10/15/2008EP1978941A2 Biodegradable non-ophthalmic implants and related methods
10/15/2008EP1944369A9 Dbait and its standalone uses thereof
10/15/2008EP1896416B1 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
10/15/2008EP1694338B1 Use of mimetics of superoxide dismutase and of reductase glutathione in the form of anticancer drugs
10/15/2008EP1689745B1 Novel macrocycles for treating tumor diseases
10/15/2008EP1660085B1 Pyridylpyrrole derivatives active as kinase inhibitors
10/15/2008EP1608397B1 S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
10/15/2008EP1605939B1 Pharmaceutical use of 1-azabicyclo¬ 2.2.2 octanes and a method of testing compounds for the ability of activating inactive wt p53
10/15/2008EP1585750B1 Narcistatin prodrugs
10/15/2008EP1530572B1 Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
10/15/2008EP1476423B1 Arylsulfonamidobenzylic compounds
10/15/2008EP1466614B1 Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon
10/15/2008EP1465617B1 Process for affecting neurologic progression
10/15/2008EP1458723B1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
10/15/2008EP1458722B1 Pyrrolopyrimidines as phosphodiesterase vii inhibitors
10/15/2008EP1453798B1 (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
10/15/2008EP1446162B1 Combination motif immune stimulatory oligonucleotides with improved activity
10/15/2008EP1444202B1 Novel metalloproteinase inhibitors
10/15/2008EP1435991B1 Use of aplidine for the treatment of pancreatic cancer
10/15/2008EP1411982B1 Modulators of p-selectin glycoprotein ligand 1
10/15/2008EP1373257B9 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/15/2008EP1372704B1 Monocyte-specific particulate delivery vehicle
10/15/2008EP1339871B1 Diagnosis and treatment of tumor-suppressor associated disorders
10/15/2008EP1319008B1 Water soluble rapamycin esters
10/15/2008EP1308439B1 Proline derivatives and use thereof as drugs
10/15/2008EP1303600B1 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
1 ... 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 ... 2211